KAUST and Janssen Pharmaceutical (Johnson & Johnson) are collaborating to research and innovate in neglected tropical diseases, focusing on dengue fever. They signed an MoU to establish a dengue fever research program and an infectious disease R&D center at KAUST's National BioPark. The partnership marks Johnson & Johnson's first university collaboration in Saudi Arabia. Why it matters: This collaboration signifies a major step in localizing disease research within Saudi Arabia and leveraging KAUST's AI, genomics, and data simulation expertise to address global health challenges.
KAUST and King Abdulaziz University (KAU) have signed a memorandum of understanding (MoU) to collaborate and fund scientific research. The collaboration will focus on areas including cancer research, energy harvesting and storage, solar technology, renewable energy, and desert agriculture. The MoU was signed by Donal Bradley, KAUST VP for Research, and Yusuf Al Turki, KAU VP for Graduate Studies and Scientific Research. Why it matters: This partnership between two leading Saudi universities will help advance research and development in areas critical to Saudi Vision 2030.
KAUST and Boeing renewed their Master Research Agreement (MRA) on September 1. The agreement aims to boost collaborative research on next-generation aerospace technologies. The renewed MRA signifies a continued partnership between the Saudi university and the American aerospace company. Why it matters: This agreement can foster innovation in aerospace within Saudi Arabia and aligns with the Kingdom's broader technology development goals.
The Research Products Development Company (RPDC) signed an agreement with The Saudi Vaccine and Biomanufacturing Center (SVBC) to establish a research and industrial center in Saudi Arabia for vaccine and biopharmaceutical development. Supported by KACST and hosted by KAUST, the SVBC will provide a state-of-the-art facility and a training platform. Cooperation agreements were also signed with GE for equipment supply and with Fujifilm Dayosent Biotechnology for MERS-CoV treatment development. Why it matters: This initiative aims to localize vaccine and advanced treatment industries in Saudi Arabia, create technical jobs, and reduce reliance on imports in line with Vision 2030.
KAUST's Computational Bioscience Research Center (CBRC) and King Abdulaziz City for Science and Technology (KACST) have collaborated on research into methicillin-resistant Staphylococcus aureus (MRSA) within Saudi Arabia, starting in July 2018. The two-year project aims to understand MRSA drug resistance mechanisms specific to the Kingdom and its regions, with the goal of developing public health strategies. The project involves sequencing samples and performing bioinformatics analysis to support a network of researchers in the country. Why it matters: This initiative enhances Saudi Arabia's capacity to predict, prevent, and control infectious diseases, aligning with national health objectives and building local expertise in computational bioscience.